Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25422205)

  • 1. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
    Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
    Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
    Winterhalder R; Hoesli P; Delmore G; Pederiva S; Bressoud A; Hermann F; von Moos R;
    Oncology; 2011; 80(1-2):29-33. PubMed ID: 21606661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
    Chan A; Tan SH; Low XH; Yap KY
    Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
    Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
    Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over compliance with capecitabine oral chemotherapy.
    Allen J; Williamson S
    Int J Clin Pharm; 2014 Apr; 36(2):271-3. PubMed ID: 24532364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
    Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J
    World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
    Pisano C; Morabito A; Sorio R; Breda E; Lauria R; Gebbia V; Scaltriti L; Scalone S; Zagonel V; Greggi S; Beneduce G; Losito S; Gallo C; Di Maio M; Forestieri V; Pignata S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1021-7. PubMed ID: 19266200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onycholysis associated with capecitabine in patients with breast cancer.
    Hogeling M; Howard J; Kanigsberg N; Finkelstein H
    J Cutan Med Surg; 2008; 12(2):93-5. PubMed ID: 18346407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
    Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
    Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary syndrome induced by capecitabine therapy.
    Wijesinghe N; Thompson PI; McAlister H
    Heart Lung Circ; 2006 Oct; 15(5):337-9. PubMed ID: 16697705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of capecitabine: a review.
    Mikhail SE; Sun JF; Marshall JL
    Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
    Chan HY; Ng CM; Tiu SC; Chan AO; Shek CC
    Hong Kong Med J; 2012 Dec; 18(6):526-9. PubMed ID: 23223655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine induced colitis.
    Maggo G; Grover SC; Grin A
    Pathol Res Pract; 2014 Sep; 210(9):606-8. PubMed ID: 24947412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ileitis following capecitabine use].
    Bouma G; Imholz AL
    Ned Tijdschr Geneeskd; 2011; 155():A3064. PubMed ID: 21486509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine in gastric cancer.
    Okines A; Chau I; Cunningham D
    Drugs Today (Barc); 2008 Aug; 44(8):629-40. PubMed ID: 18846273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.